Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Uveal Neoplasms

• Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
• Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
• IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
• Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
• Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
• Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
• Adjuvant Melatonin for Uveal Melanoma
• Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
• A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
• Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
• Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
• A Study of Concurrent Stereotactic Body Radiotherapy With Ipi and Nivo in Metastatic Uveal Melanoma
• Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
• Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
• FHD-286 in Subjects With Metastatic Uveal Melanoma
• Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
• Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
• Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
• Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
• Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
• Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
• Dexamethasone Implant for Retinal Detachment in Uveal Melanoma
• Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
• Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
• A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
• Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
• Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
• Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
• Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
• Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
• Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
• Intermittent Selumetinib for Uveal Melanoma
• Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
• Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
• Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
• A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
• A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
• Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
• Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
• Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
• Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
• Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
• Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
• Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
• Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
• Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
• A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
• Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
• Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
• A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
• Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
• Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
• Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
• A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
• Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
• RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
• Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
• Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
• Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
• Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
• Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
• Treatment With Intravitreal Avastin for Large Uveal Melanomas
• Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
• Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
• Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
• Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
• Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
• Dendritic Cell Vaccination During Lymphoid Reconstruction
• AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
• PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma
• Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
• Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
• Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma
• Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
• Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma
• Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
• Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
• Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma